Aclerastide (DSC-127; NorLeu-3-A(1-7)) is an angiotensin analogue that is being developed by Derma Sciences (a subsidiary of Integra LifeSciences) for the treatment for wounds such as diabetic foot ulcer and surgical scars. The mechanisms of action include induction of progenitor proliferation, accelerated vascularization, collagen deposition, and re-epithelialization. Aclerastide recently failed in phase III clinical trials for treatment of diabetic foot ulcers. Phase I development of aclerastide ophthalmic solution is ongoing in the US.
Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Wed Apr 02 08:16:24 GMT 2025
by
admin
on
Wed Apr 02 08:16:24 GMT 2025
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
YYD6UT8T47
|
| Record Status |
FAILED
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
414813
Created by
admin on Wed Apr 02 08:16:24 GMT 2025 , Edited by admin on Wed Apr 02 08:16:24 GMT 2025
|
||
|
FDA ORPHAN DRUG |
414713
Created by
admin on Wed Apr 02 08:16:24 GMT 2025 , Edited by admin on Wed Apr 02 08:16:24 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9811551
Created by
admin on Wed Apr 02 08:16:24 GMT 2025 , Edited by admin on Wed Apr 02 08:16:24 GMT 2025
|
PRIMARY | |||
|
DB12631
Created by
admin on Wed Apr 02 08:16:24 GMT 2025 , Edited by admin on Wed Apr 02 08:16:24 GMT 2025
|
PRIMARY | |||
|
C169759
Created by
admin on Wed Apr 02 08:16:24 GMT 2025 , Edited by admin on Wed Apr 02 08:16:24 GMT 2025
|
PRIMARY | |||
|
9877
Created by
admin on Wed Apr 02 08:16:24 GMT 2025 , Edited by admin on Wed Apr 02 08:16:24 GMT 2025
|
PRIMARY | |||
|
300000025251
Created by
admin on Wed Apr 02 08:16:24 GMT 2025 , Edited by admin on Wed Apr 02 08:16:24 GMT 2025
|
PRIMARY | |||
|
YYD6UT8T47
Created by
admin on Wed Apr 02 08:16:24 GMT 2025 , Edited by admin on Wed Apr 02 08:16:24 GMT 2025
|
PRIMARY | |||
|
227803-63-6
Created by
admin on Wed Apr 02 08:16:24 GMT 2025 , Edited by admin on Wed Apr 02 08:16:24 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
Structural Modifications
| Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
|---|---|---|---|---|---|---|
| AMINO ACID SUBSTITUTION | [1_3] | NORLEUCINE | 832C8OV84S |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|
||||
| Molecular Formula | CHEMICAL |
|